This is an early regulatory step for a pre-revenue micro-cap. Monitor for patient enrollment updates and safety/efficacy data from the Phase 1/2a trial. The stock is highly speculative and may see volatility on news flow, but fundamental value is unproven.
Price Chart
Executive Summary
BriaCell received FDA clearance to begin a Phase 1/2a clinical trial for Bria-BRES+, its next-generation personalized immunotherapy for metastatic breast cancer. This is an early-stage regulatory milestone for a micro-cap biotech with no approved products, and the stock's $7M market cap reflects high risk. The IND clearance enables clinical advancement but does not guarantee efficacy or commercial success.
Key Facts
- FDA cleared IND for Bria-BRES+, a personalized cell-based immunotherapy for metastatic breast cancer.
- Phase 1/2a study planned to initiate in the coming months.
- BriaCell has a market cap of ~$7M and no approved products.
- Prior Bria-OTS program showed a complete resolution of a lung metastasis in one patient at 2 months, confirmed through 11 months.
Financial Impact
No financial figures disclosed; early-stage clinical milestone with no revenue or deal value.
Risk Factors
- Clinical trial failure or safety issues could halt development.
- No approved products or revenue; high cash burn risk.
- Micro-cap with low liquidity and high volatility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288700 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | Press Release | $0.8800 $1.02 | ▲ +16.02% | ▲ +13.76% | — |
Aug 5, 2026 11w ago | Press Release | $0.8600 | awaiting T+20 | — | — |
Jul 16, 2026 14w ago | Press Release | $0.9000 $0.8250 | ▼ −8.33% | ▼ −11.95% | — |
May 26, 2026 21w ago | Press Release | — | awaiting T+20 | — | — |
May 22, 2026 22w ago | Press Release | — | awaiting T+20 | — | — |
May 13, 2026 23w ago | Press Release | $1.05 $0.6999 | ▼ −33.34% | ▼ −32.73% | — |
May 6, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
Apr 21, 2026 26w ago | Press Release | — | awaiting T+20 | — | — |
Apr 20, 2026 27w ago | Press Release | — | awaiting T+20 | — | — |
Mar 18, 2026 31w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers